Dania Therapeutics ApS
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Dania Therapeutics ApS - overview
Established
2021
Location
Hellerup, -, Denmark
Primary Industry
Biotechnology
About
Based in Hellerup, Denmark, and founded in 2021, Dania Therapeutics ApS, also known as Dania Tx, operates as a biotechnology company. The company was founded by Kristian Helin, Karl Agger, and Kim Andersen. In October 2023, Dania Therapeutics ApS raised DKK 15 million in venture funding from the Lundbeck Foundation, Eir Ventures, the Export and Investment Fund of Denmark (EIFO), and UCPH Ventures. Dania Therapeutics develops small-molecule drugs aimed at treating Acute Myeloid Leukemia (AML) and other cancers.
The company collaborates with academic institutions, such as the University of Copenhagen, for cancer research. The company plans to use the funds raised in October 2023 to expand its biotech research and develop treatments.
Current Investors
Lundbeck Foundation, Eir Ventures, Export and Investment Fund of Denmark
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
Dania Therapeutics ApS - financials
| Fiscal Year Ended | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|
| Revenue (USD) | - | - | - |
| % Revenue Growth (YoY) | - | - | - |
| EBITDA (USD) | - | - | - |
| Operating Income (USD) | - | - | - |
| Operating Margin | - | - | - |
| % EBITDA Margin | - | - | - |
| NET Income (USD) | - | - | - |
| % Net Margin | - | - | - |
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.